#USA #Halia Therapeutics #Lehi #NEK7 #inflammasome inhibitors

Halia Therapeutics to Present at BIO Investment & Growth Summit

Halia Therapeutics, a pioneering clinical-stage biopharmaceutical company, has made headlines by announcing its presentation at the highly anticipated BIO Investment & Growth Summit scheduled for March 2, 2026. The summit, which attracts industry-leading professionals, will take place in Ballroom I, Salon C, providing a platform for Halia to showcase its transformative approaches in biotherapeutic development.

Leadership Insights

The presentation will be led by Dr. David Bearss, the Chief Executive Officer of Halia Therapeutics. Dr. Bearss is set to share an insightful overview of the company's strategic direction, its innovative platform, and the progress of its clinical programs aimed at tackling inflammation-driven diseases. This event serves as a significant opportunity for Halia to engage with investors and thought leaders in the biotechnology field, highlighting the company's commitment to advancing healthcare solutions.

Focus on NEK7

At the forefront of Halia’s presentation is NEK7, a vital regulator involved in the assembly and activation of the NLRP3 inflammasome. This molecular pathway has critical implications in various chronic conditions characterized by inflammation, including those affecting hematology, cardiometabolic health, and pain management. By targeting NEK7, Halia Therapeutics aims to implement a novel approach that addresses inflammation at its source, rather than just mitigating its symptoms. This strategy positions Halia's therapies as differentiated solutions in an increasingly crowded market.

About Halia Therapeutics

Founded with a vision to develop first-in-class inflammasome inhibitors, Halia Therapeutics is at the forefront of biopharmaceutical innovation. The company seeks to revolutionize the treatment of inflammation-related disorders by directly targeting the underlying mechanisms of these diseases. With a focus on pioneering therapies, Halia is committed to addressing unmet medical needs and enhancing patient outcomes globally.

The BIO Investment & Growth Summit is a key event that gathers investors and industry experts to discuss emerging trends and innovations within the life sciences. Halia’s participation underscores its strategic importance within the sector, highlighting its innovative research and dedication to advancing medical science. As the biopharmaceutical landscape evolves, Halia Therapeutics positions itself as a leader in developing targeted therapies that promise to make a significant impact on patients' lives.

Conclusion

As Halia prepares for this notable event, the company stands ready to demonstrate its commitment to advancing scientific knowledge and improving patient health outcomes through innovative biopharmaceutical solutions. This event could mark a pivotal moment not just for Halia Therapeutics but for the broader field of biotechnology as well. Stakeholders are encouraged to engage with Halia’s presentation to explore the future of therapeutic innovation in inflammation management.

For media inquiries or further information, please contact Taylor Avei, Director of Business Development at Halia Therapeutics.